Aftertreated Polymer (e.g., Grafting, Blocking, Etc.) Patents (Class 424/78.17)
  • Patent number: 11896733
    Abstract: According to an illustrative embodiment a method to promote healing of a wound is provided comprising contacting the wound with a biologically active composition comprising a lipoic acid derivative and gelatin. In another embodiment a wound dressing is provided comprising a scaffold coated with a biologically active composition comprising a lipoic acid derivative. In a further embodiment, a system is provided for treating a tissue site of a patient, the system comprising a reduced-pressure source to supply reduced pressure, a manifold to distribute reduced pressure to a tissue site and a scaffold coated with a biologically active composition comprising a lipoic acid derivative. Methods for producing such a system and scaffold are also disclosed.
    Type: Grant
    Filed: July 13, 2021
    Date of Patent: February 13, 2024
    Assignee: 3M Innovative Properties Company
    Inventors: Dmitry Zimnitsky, Jenny Finkbiner, Blane Sanders
  • Patent number: 11884781
    Abstract: The present invention relates to supramolecular biomedical polymers comprising quadruple hydrogen bonding units and to a process for preparing such a supramolecular biomedical polymer and porous biomedical implants thereof. The supramolecular biomedical polymers are particularly suitable for the production of porous biomedical implants that need high strength, elasticity, durability, and slow biodegradation, e.g. medical implants for living tissue regeneration within a mammal, such as the treatment of cardio-vascular diseases, medical prolapses, and hernias.
    Type: Grant
    Filed: May 19, 2020
    Date of Patent: January 30, 2024
    Assignee: SUPRAPOLIX B.V.
    Inventors: Tristan Mes, Anton Willem Bosman, Joris Wilhelmus Peeters, Henricus Marie Janssen
  • Patent number: 11865205
    Abstract: A method of targeting to the synovial tissue biodegradable drug delivery compositions or morselizing biodegradable drug delivery compositions are described. The biodegradable drug composition comprises a triblock copolymer containing a polyester and a polyethylene glycol and a diblock copolymer containing a polyester and an end-capped polyethylene glycol, as well as at least one pharmaceutically active principle is disclosed.
    Type: Grant
    Filed: January 25, 2021
    Date of Patent: January 9, 2024
    Assignee: MEDINCELL S.A.
    Inventors: Georges Gaudriault, Sylvestre Grizot, Mark Hurtig, Matthew Shive
  • Patent number: 11701375
    Abstract: Polymeric compositions are provided that include a poly(ethylene glycol), a viscoelastic polymer, and an antioxidant, where, in polymerized form, the compositions have a refractive index of about 1.30 to about 1.40. Methods of synthesizing the compositions are also provided and include the steps of heating an amount of water; adding a buffering agent to the water to form a buffer solution; mixing a poly(ethylene glycol) and a viscoelastic polymer into the buffer solution to form a reactive mixture; adding a plurality of antioxidant particles to the reactive mixture; and removing suspended gas bubbles from the reactive mixture. Methods of preventing oxidative damage to an eye lens of a subject are further provided and include administering the foregoing polymeric compositions to the eye lens of the subject.
    Type: Grant
    Filed: June 23, 2021
    Date of Patent: July 18, 2023
    Assignee: University of Louisville Research Foundation, Inc.
    Inventors: Tongalp H. Tezel, Andrea S. Gobin, Martin G. O'Toole
  • Patent number: 11666656
    Abstract: Polymeric conjugates comprising a polymeric matrix having associated therewith an agent that down-regulates an activity or expression of a polypeptide associated with onset or progression of melanoma, and optionally and preferably, an additional agent that acts in synergy with said agent, are provided. Synthetic methodologies for preparing these conjugates and uses thereof in treating melanoma and other cancerous diseases are also provided.
    Type: Grant
    Filed: February 24, 2017
    Date of Patent: June 6, 2023
    Assignee: Ramot at Tel-Aviv University Ltd.
    Inventors: Ronit Satchi-Fainaro, Evgeni Pisarevsky, Anat Eldar-Boock, Dikla Ben-Shushan, Yana Epshtein, Anna Scomparin
  • Patent number: 11668613
    Abstract: ABA type block copolymers as a new class of temperature sensing polymers with tunable, high temperature coefficient of resistance (TCR). A sensor includes a heater, a thermal insulator between two thermometer layers, the heater generating a thermal gradient within the thermal insulator. The thermometers give an indirect measurement of fluid flow around the sensor, based on their temperature readings. The thermometers are flexible layers including ABA block polymers.
    Type: Grant
    Filed: May 6, 2019
    Date of Patent: June 6, 2023
    Assignee: CALIFORNIA INSTITUTE OF TECHNOLOGY
    Inventors: Luca Bonanomi, Vincenzo Costanza, Chiara Daraio, Zhun Zhou
  • Patent number: 11434278
    Abstract: A polymeric scaffold useful for conjugating with a protein based recognition-molecule (PBRM) to form a PBRM-polymer-drug conjugate is described herein. The scaffold includes one or more terminal maleimido groups. Also disclosed is a PBRM-polymer-drug conjugate prepared from the scaffold. Compositions comprising the conjugates, methods of their preparation, and methods of treating various disorders with the conjugates or their compositions are also described.
    Type: Grant
    Filed: April 12, 2019
    Date of Patent: September 6, 2022
    Assignee: Asana BioSciences, LLC
    Inventors: Roger A. Smith, Nitin K. Damle, Aleksandr V. Yurkovetskiy, Mao Yin, Timothy B. Lowinger, Joshua D. Thomas, Cheri A. Stevenson, Venu R. Gurijala
  • Patent number: 11406661
    Abstract: Pharmaceutical compositions for and methods of treating an animal, including a human, and methods of preparing such compositions. The pharmaceutical compositions contain nonabsorbable compositions and may be used, for example, to treat diseases or other metabolic conditions in which removal of protons, the conjugate base of a strong acid and/or a strong acid from the gastrointestinal tract would provide physiological benefits such as normalizing serum bicarbonate concentrations and the blood pH in an animal, including a human.
    Type: Grant
    Filed: May 5, 2017
    Date of Patent: August 9, 2022
    Assignee: TRICIDA, INC.
    Inventors: Gerrit Klaerner, Eric F. Connor, Randi K. Gbur, Matthew J. Kade, Paul H. Kierstead, Jerry M. Buysse, Michael J. Cope, Kalpesh N. Biyani, Son H. Nguyen, Scott M. Tabakman
  • Patent number: 11331276
    Abstract: The present invention is a surface treated drug-loaded solid (e.g., non-porous) microparticle that aggregates in vivo to form a consolidated larger particle for medical therapy. In one embodiment, the particles are used for ocular therapy. Processes for producing the surface treated microparticle and injectable formulations which include the surface treated microparticle are also provided. When used in the eye, long-term consistent intraocular delivery can be achieved without disrupting vision and minimizing undesirable inflammatory responses.
    Type: Grant
    Filed: September 10, 2019
    Date of Patent: May 17, 2022
    Assignee: Graybug Vision, Inc.
    Inventors: Yun Yu, Joshua Kays, Ming Yang, Jeffrey L. Cleland
  • Patent number: 11318132
    Abstract: The present invention provides a composition comprising an opioid agonist, and a polymer-antagonist conjugate. The polymer-antagonist conjugate preferably does not hydrolyze upon administration to a patient, and does not bind to the opioid receptors. The covalent bond between the polymer and the antagonist in the conjugate is broken over a defined period of time to release the antagonist into the formulation. The released antagonist attenuates the liking of the agonist, thereby eliminating the incentive to the diversion of the medicines.
    Type: Grant
    Filed: April 24, 2019
    Date of Patent: May 3, 2022
    Assignee: Elysium Therapeutics, Inc.
    Inventor: Thomas E. Jenkins
  • Patent number: 11246873
    Abstract: The present invention provides methods of inducing differentiation of oligodendrocyte progenitor cells to a mature myelinating cell fate with a neurotransmitter receptor modulating agent. The present invention also provides methods of stimulating increased myelination in a subject in need thereof by administering said neurotransmitter receptor modulating agent. Methods of treating a subject having a demyelinating disease using a neurotransmitter receptor modulating agent are also provided.
    Type: Grant
    Filed: April 8, 2020
    Date of Patent: February 15, 2022
    Assignee: The Scripps Research Institute
    Inventors: Peter Schultz, Luke Lairson, Vishal Deshmukh, Costas Lyssiotis
  • Patent number: 11197887
    Abstract: Pharmaceutical compositions for and methods of treating an animal, including a human, and methods of preparing such compositions. The pharmaceutical compositions contain crosslinked amine polymers and may be used, for example, to treat diseases or other metabolic conditions in which removal of protons and/or chloride ions from the gastrointestinal tract would provide physiological benefits such as normalizing serum bicarbonate concentrations and the blood pH in an animal, including a human.
    Type: Grant
    Filed: August 16, 2019
    Date of Patent: December 14, 2021
    Assignee: TRICIDA, INC.
    Inventors: Gerrit Klaerner, Eric F. Connor, Randi K. Gbur, Matthew J. Kade, Paul H. Kierstead, Jerry M. Buysse, Michael J. Cope, Kalpesh N. Biyani, Son H. Nguyen, Scott M. Tabakman
  • Patent number: 11185615
    Abstract: A method of making a solution including poly(ethylene terephthalate). The method includes dissolving poly(ethylene terephthalate) in a solvent mixture to form a solution, the solvent mixture including two solvent components. A Hansen Solubility Parameter Distance between the solvent mixture and HSP coordinates having a dispersion HSP of 18.02 MPa0.5, a polar HSP of 5.56 MPa0.5, and a hydrogen bonding HSP of 14.27 MPa0.5 is less than about 2 MPa0.5.
    Type: Grant
    Filed: October 10, 2019
    Date of Patent: November 30, 2021
    Assignee: Cardiac Pacemakers, Inc.
    Inventors: Joseph T. Delaney, Jr., David R. Wulfman, Adeniyi O. Aremu, Adegbola O. Adenusi
  • Patent number: 11179467
    Abstract: Disclosed are an exenatide modifier for connecting the exenatide to a fatty chain with a carboxy in the terminus thereof by means of a hydrophilic connecting arm, and a use thereof in preparing drugs serving as a GLP-1 receptor agonist; a use in preparing drugs for preventing and/or treating diseases and/or symptoms associated with a low GLP-1 receptor activity; a use in preparing drugs for diseases and/or symptoms associated with glycometabolism; a use in preparing drugs for diabetes; a use in preparing drugs for fatty liver disease, and a use in preparing drugs for losing weight.
    Type: Grant
    Filed: September 13, 2016
    Date of Patent: November 23, 2021
    Assignee: BRIGHTGENE BIO-MEDICAL TECHNOLOGY CO., LTD.
    Inventors: Jiandong Yuan, Yangqing Huang, Yunsong Song, Fang Yuan
  • Patent number: 11160798
    Abstract: A method of treating or preventing a neuroinflammatory and/or neurodegenerative disease in a subject by administering a pharmaceutically effective amount of a CB2 receptor agonist is described. The CB2 receptor agonist can be a compound according to formula I or a pharmaceutically acceptable salt thereof, with R1 and R2 as defined herein. Administration of the CB2 receptor agonist activates CB2 receptors in the microglia, and can restore syntaptic plasticity, cognition, and memory in subjects having elevated levels of amyloid-ßpeptide in the brain.
    Type: Grant
    Filed: November 22, 2019
    Date of Patent: November 2, 2021
    Assignee: THE CLEVELAND CLINIC FOUNDATION
    Inventors: Mohamed Naguib Attala, David L. Brown
  • Patent number: 11007148
    Abstract: The present invention provides an amphiphilic block copolymer for drug delivery and a controlled release system comprising the same copolymer. The copolymer comprises at least one hydrophilic block and at least one hydrophobic block, wherein the hydrophobic block is selected from the group consisting of acrylates, methacrylates, acrylamides, methacrylamides, vinylethers and their aromatic derivatives, wherein at least one hydrophobic block contains an aryl group, which is bound to the hydrophobic block with a degradable linker. The controlled release system of the invention shows high stability and high drug retention when administered in vivo enabling accumulation and drug release at the site of action.
    Type: Grant
    Filed: August 11, 2015
    Date of Patent: May 18, 2021
    Assignee: Rheinisch-Westfälische Technische Hochschule (RWTH) Aachen
    Inventors: Wilhelmus Everhardus Hennink, Yang Shi, Cornelus Franciscus van Nostrum
  • Patent number: 10954266
    Abstract: The present invention relates to a method for the purification of peptides which are produced by solid phase peptide synthesis (SPPS) and corresponding linker molecules for use in said method.
    Type: Grant
    Filed: January 30, 2017
    Date of Patent: March 23, 2021
    Assignee: BELYNTIC GMBH
    Inventors: Robert Zitterbart, Oliver Seitz
  • Patent number: 10947317
    Abstract: This disclosure provides NaPi2b-targeted antibody-drug conjugates (e.g., NaPi2b-targeted antibody-polymer-drug conjugates) that specifically bind to the extracellular region of SLC34A2, and to methods of using such conjugates in a variety of therapeutic, diagnostic, and prophylactic indications.
    Type: Grant
    Filed: March 13, 2017
    Date of Patent: March 16, 2021
    Assignee: Mersana Therapeutics, Inc.
    Inventors: Donald A. Bergstrom, Natalya D. Bodyak, Timothy B. Lowinger, Peter U. Park, Laura L. Poling, Aleksandr V. Yurkovetskiy
  • Patent number: 10869863
    Abstract: Disclosed is a multi-arm targeting drug conjugate modified by a water-soluble polymer; the drug conjugate has the structural formula of (III). In formula (III), R is an organic core, POLY is a polymer, L is a multivalent linker, T is a targeting molecule, D is a camptothecin-based drug, and q is any integer between 3 and 8. The drug conjugate may improve the poor water solubility, high toxicity and low bioavailability of camptothecin-based drugs.
    Type: Grant
    Filed: May 15, 2017
    Date of Patent: December 22, 2020
    Assignee: BrightGene Bio-Medical Technology Co., Ltd.
    Inventors: Jiandong Yuan, Yangqing Huang, Yunsong Song, Fang Yuan
  • Patent number: 10831169
    Abstract: The present disclosure relates to a manufacturing system, method and control circuitry for quality assured manufacturing of at least two biopharmaceutical products. The manufacturing system comprises a warehouse facility, a hydration facility, and at least two biopharmaceutical manufacturing facilities, wherein the warehouse facility and hydration facility are comprised in the macro structure. Each biopharmaceutical manufacturing facility is comprised in a respective micro node, and a control facility in the macro structure is configured to control interoperability of the macro structure and the micro nodes by means of a network spine interconnecting the macro structure with each micro node.
    Type: Grant
    Filed: June 20, 2019
    Date of Patent: November 10, 2020
    Assignee: GLOBAL LIFE SCIENCES SOLUTIONS USA LLC
    Inventors: Steve Robert Gravallese, Jason Naylor, Edwin Brian Taylor, Sven Frie, Patrick McMahon
  • Patent number: 10800749
    Abstract: In alternative embodiments, the invention provides nucleophilic hydroxyimino-acetamido alkylamine antidotes that cross the blood-brain barrier (BBB) to catalyze the hydrolysis of organophosphate (OP)-inhibited human acetylcholinesterase (hAChE) in the central nerve system (CNS). The hydroxyimino-acetamido alkylamines of the invention are designed to fit within AChE active center gorge dimensions, bind with reasonable affinity, and react with the conjugated phosphate atom in the gorge. The hydroxyimino-acetamido alkylamines of the invention are also designed to possess ionization states that govern affinity and reactivity for the two linked hAChE re-activation steps.
    Type: Grant
    Filed: July 11, 2019
    Date of Patent: October 13, 2020
    Assignees: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, THE SCRIPPS RESEARCH INSTITUTE
    Inventors: Palmer Taylor, Zoran Radic, K. Barry Sharpless, Valery Fokin, Rakesh Sit
  • Patent number: 10772844
    Abstract: A hybrid hydrogel including a hydrogel material and a plurality of first hybrid nanoparticles is provided. The plurality of first hybrid nanoparticles are conjugated to the hydrogel material, wherein each of the first hybrid nanoparticles includes a first positive-charged polysaccharide and a first negative-charged polysaccharide. The first positive-charged polysaccharide is located at an inner core of the first hybrid nanoparticles. The first negative-charged polysaccharide is located at an outer shell of the first hybrid nanoparticles and carries a plurality of first growth factors. The first negative-charged polysaccharide and the first positive-charged polysaccharide are electrostatically attracted to form the first hybrid nanoparticles. A method of fabricating the hybrid hydrogel is also provided.
    Type: Grant
    Filed: November 5, 2018
    Date of Patent: September 15, 2020
    Assignee: National Tsing Hua University
    Inventors: Tzu-Wei Wang, Wei-Hong Jian
  • Patent number: 10577406
    Abstract: Disclosed are methods and compositions that employ FKBP-L polypeptides for modulating angiogenesis and/or tumor metastasis. The FKBP-L polypeptides may be used for the treatment of disorders mediated by angiogenesis such as cancer.
    Type: Grant
    Filed: May 31, 2016
    Date of Patent: March 3, 2020
    Assignee: ALMAC DISCOVERY LIMITED
    Inventors: Tracy Robson, Andrea Valentine, Martin Gerard O'Rourke, David Hirst
  • Patent number: 10532125
    Abstract: The presently-disclosed subject matter includes a compound comprising a first monomer, which is allyl-functionalized and crosslinkable, and a second monomer, which is not crosslinkable. In some embodiments the compounds are photocrosslinkable, and in certain embodiments are photocrosslinkable by ultraviolet light. Also provided are shape memory vascular grafts comprised the of present compounds that can transition from a temporary shape to an original shape when heated above a melting temperature of the graft. Still further provided are methods for treating vascular conditions that utilize embodiments of the present grafts.
    Type: Grant
    Filed: June 27, 2014
    Date of Patent: January 14, 2020
    Assignee: Vanderbilt University
    Inventors: Hak-Joon Sung, Timothy C. Boire, Mukesh K. Gupta, Angela L. Zachman, Sue Hyun-Lee, Colleen M. Brophy
  • Patent number: 10501575
    Abstract: Disclosed are biomimetic imageable polymeric materials that include a polymer or copolymer and a covalently-linked contrasting agent where the disclosed films are both bioresorbable and visible by X-ray fluoroscopic imaging and/or magnetic resonance imaging. The invention also provides methods of preparing the polymeric materials and their use in and as implantable medical devices.
    Type: Grant
    Filed: May 26, 2016
    Date of Patent: December 10, 2019
    Assignee: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Tre Raymond Welch, Amy Claire Kauffman
  • Patent number: 10400064
    Abstract: The invention provides polymer compositions, compounds, processes, and methods of use of the polymers for drug delivery, biodegradable consumer plastics, or solvents for Li-based batteries or supercapacitors.
    Type: Grant
    Filed: November 25, 2015
    Date of Patent: September 3, 2019
    Assignee: Trustees of Boston University
    Inventors: Mark W. Grinstaff, Heng Zhang, Iriny Ekladious, Marlena D. Konieczynska
  • Patent number: 10398724
    Abstract: The invention relates to bulking agents and apparatus and methods for using the disclosed bulking agents. The bulking agents can be used to treat such conditions as urinary and fecal incontinence, gastro-esophageal reflux, ancurismal blockages, and cosmetic deformities. The invention also relates to an injection method that reduces the injection pressure required to place the bulking agents.
    Type: Grant
    Filed: November 18, 2013
    Date of Patent: September 3, 2019
    Assignee: Boston Scientific Scimed, Inc.
    Inventors: George Bourne, Michael Madden, Arthur R. Madenjian, Doreen Rao, Marcia Buiser, Jianmin Li, Raymond Rackley, Barry N. Gellman
  • Patent number: 10363259
    Abstract: Fulvestrant formulations suitable for intramuscular injection at concentration in excess of 40 mg/ml in the absence of castor oil and castor oil derivatives are disclosed.
    Type: Grant
    Filed: October 20, 2017
    Date of Patent: July 30, 2019
    Assignee: EAGLE PHARMACEUTICALS, INC.
    Inventor: Nageswara R. Palepu
  • Patent number: 10363538
    Abstract: A substrate for biochips, in which carboxyl groups are immobilized on a substrate whose surface at least is composed of carbon; and a method for producing the substrate are disclosed. The substrate for biochips comprises a substrate whose surface at least is composed of carbon; and an acrylic polymer having free carboxyl groups in the molecular structure thereof, which acrylic polymer is immobilized on the surface of the substrate. The method for producing the substrate comprises irradiating the substrate whose surface at least is composed of carbon with ultraviolet light during the acrylic polymer having free carboxyl groups in the molecular structure thereof contacts the substrate.
    Type: Grant
    Filed: October 5, 2017
    Date of Patent: July 30, 2019
    Assignee: NIPPON LIGHT METAL COMPANY, LTD.
    Inventors: Yasushi Takebayashi, Ryo Morishita, Kei Yamaguchi
  • Patent number: 10342797
    Abstract: Disclosed herein are methods and compositions to improve the solubility of therapeutic agents. In one embodiment, a method of improving solubility of a therapeutic agent includes mixing fullerene in a lipid solution to form a lipofullerene mixture, and mixing the therapeutic agent with the lipofullerene mixture.
    Type: Grant
    Filed: November 2, 2016
    Date of Patent: July 9, 2019
    Assignee: LivePet, LLC
    Inventors: Ian Mitchell, Daniel David Bensimon, Ayyappan Subbiah, Rajashekharam Malyala
  • Patent number: 10336708
    Abstract: A novel imidazole compound that yields a surface treatment liquid that is very effective at suppressing migration and oxidation of a wiring surface; a metal surface treatment liquid that contains the imidazole compound; a metal surface treatment method that uses the metal surface treatment liquid; and a laminate production method that uses the surface treatment liquid. A metal is surface-treated using the surface treatment liquid which includes a saturated fatty acid or a saturated fatty acid ester of a specific structure, in which a prescribed position is substituted by an aromatic group of a prescribed structure and an imidazolyl group that may have a substituent group.
    Type: Grant
    Filed: August 27, 2015
    Date of Patent: July 2, 2019
    Assignee: TOKYO OHKA KOGYO CO., LTD.
    Inventors: Tatsuro Ishikawa, Kunihiro Noda, Yasuhide Ohuchi, Hiroki Chisaka, Dai Shiota, Yukitsugu Maeda, Takafumi Imoto, Kouhei Fujita, Yasuyuki Akai
  • Patent number: 10266809
    Abstract: A process for making an oligo(alkylene glycol) functionalized co-polyisocyanopeptide, wherein the process includes the steps of: i) copolymerizing a first comonomer of an oligo(alkylene glycol) functionalized isocyanopeptide grafted with a linking group and a second comonomer of a non-grafted oligo(alkylene glycol) functionalized isocyanopeptide, wherein the molar ratio between the first comonomer and the second comonomer is 1:500 and 1:30 and ii) adding a reactant of a spacer unit and a cell adhesion factor to the copolymer obtained by step i), wherein the spacer unit is represented by general formula A-L-B, wherein the linking group and group A are chosen to react and form a first coupling and the cell adhesion factor and group B are chosen to react and form a second coupling, wherein the first coupling and the second coupling are independently selected from the group consisting of alkyne-azide coupling, dibenzocyclooctyne-azide coupling, oxanorbornmadiene-based-azide couplings, vinylsulphone-thiol coupling
    Type: Grant
    Filed: July 16, 2014
    Date of Patent: April 23, 2019
    Assignee: STICHTING KATHOLIEKE UNIVERSITEIT
    Inventors: Alan Edward Rowan, Zaskia Hillet Eksteen Akeroyd, Christopher Wilson, Petrus Johannes Geutjes, Wouter F. J. Feitz, Egbert Oosterwijk
  • Patent number: 10195135
    Abstract: The present invention relates to an organopolysiloxane graft polymer including an organopolysiloxane segment as a main chain thereof and an unsaturated monomer-derived copolymer segment containing a repeating unit derived from an unsaturated monomer containing a carboxylic acid or a carboxylic acid salt as a side chain thereof, in which a content of the organopolysiloxane segment in the organopolysiloxane graft polymer is 35 to 59% by mass, a content of the repeating unit derived from the unsaturated monomer containing a carboxylic acid or a carboxylic acid salt in the organopolysiloxane graft polymer is 4 to 17% by mass, and a content of a repeating unit derived from an unsaturated monomer whose homopolymer has a glass transition point of not lower than 150° C.
    Type: Grant
    Filed: November 11, 2013
    Date of Patent: February 5, 2019
    Assignee: KAO CORPORATION
    Inventors: Satomi Nakazono, Ryosuke Fujii
  • Patent number: 10154956
    Abstract: Provided herein are methods of suppressing viral nucleic acid, e.g. double-stranded (ds) DNA, genome release from or packaging of viruses having their nucleic acid genome packaged under stress in their capsid, and compositions useful for that purpose. The methods alter the ionic environment of the nucleic acid within the capsid and thereby prevent release of, and/or interfere with packaging of the viral genome.
    Type: Grant
    Filed: July 28, 2016
    Date of Patent: December 18, 2018
    Assignee: Carnegie Mellon University
    Inventor: Alex Evilevitch
  • Patent number: 10149885
    Abstract: A microbial infection in an eye of a subject is treated or prevented by topically administering to the eye an effective amount of a macromolecule or a pharmaceutically acceptable salt thereof that includes a dendrimer of 1 to 8 generations with one or more sulfonic acid- or sulfonate-containing moieties attached to one or more surface groups of the outermost generation of the dendrimer. Compositions containing the macromolecule or salt are useful in these methods.
    Type: Grant
    Filed: September 13, 2013
    Date of Patent: December 11, 2018
    Assignee: STARPHARMA PTY LIMITED
    Inventors: Jacinth Kincaid Fairley, Colin Paul Barrett, Jeremy Robert Arthur Paull
  • Patent number: 10022453
    Abstract: The present application relates to novel antibody drug conjugates (ADCs), to active metabolites of these ADCs, to processes for preparing these ADCs, to the use of these ADCs for the treatment and/or prophylaxis of diseases and to the use of these ADCs for preparing medicaments for treatment and/or prevention of diseases, in particular hyperproliferative and/or angiogenic disorders such as, for example, cancer diseases. Such treatments can be carried out as monotherapy or else in combination with other medicaments or further therapeutic measures.
    Type: Grant
    Filed: December 10, 2014
    Date of Patent: July 17, 2018
    Assignee: BAYER PHARMA AKTIENGESELLSCHAFT
    Inventors: Hans-Georg Lerchen, Sven Wittrock, Nils Griebenow, Beatrix Stelte-Ludwig, Anette Sommer, Sandra Berndt, Christoph Mahlert, Mario Lobell, Carsten Terjung, Simone Greven, Yolanda Cancho Grande
  • Patent number: 9999675
    Abstract: Disclosed herein is a delivery composition for administering a hydrophobic active agent. In one embodiment, a delivery composition for local administration of a hydrophobic active agent to a tissue or organ of a patient is disclosed. In one embodiment, the delivery composition includes a cationic delivery agent, a therapeutically effective amount of a hydrophobic active agent and a pharmaceutically acceptable aqueous carrier. In one embodiment, the cationic delivery agent includes polyethyleneimine (PEI). In a more specific embodiment, the cationic delivery agent includes branched PEI. Methods of making the delivery composition, as well as kits and methods of use are also disclosed.
    Type: Grant
    Filed: November 21, 2016
    Date of Patent: June 19, 2018
    Assignee: Surmodics, Inc.
    Inventors: Joseph Ventura, Shannon Wadman, Joram Slager, Joseph Schmidt McGonigle, Robert W. Hergenrother
  • Patent number: 9993500
    Abstract: Pharmaceutical compositions for and methods of treating an animal, including a human, and methods of preparing such compositions. The pharmaceutical compositions contain crosslinked amine polymers and may be used, for example, to treat diseases or other metabolic conditions in which removal of protons and/or chloride ions from the gastrointestinal tract would provide physiological benefits such as normalizing serum bicarbonate concentrations and the blood pH in an animal, including a human.
    Type: Grant
    Filed: September 26, 2017
    Date of Patent: June 12, 2018
    Assignee: TRICIDA, INC.
    Inventors: Gerrit Klaerner, Eric F. Connor, Randi K. Gbur, Matthew J. Kade, Paul H. Kierstead, Jerry M. Buysse, Michael J. Cope, Kalpesh N. Biyani, Son H. Nguyen, Scott M. Tabakman
  • Patent number: 9974188
    Abstract: A process for forming a graphene circuit pattern on an object is described. A graphene layer is grown on a metal foil. A bonding layer is formed on a protective film and a surface of the bonding layer is roughened. The graphene layer is transferred onto the roughened surface of the bonding layer. The protective film is removed and the bonding layer is laminated to a first core dielectric substrate. The metal foil is etched away. Thereafter the graphene layer is etched using oxygen plasma etching to form graphene circuits on the first core dielectric substrate. The first core dielectric substrate having graphene circuits thereon is bonded together with a second core dielectric substrate wherein the graphene circuits are on a side facing the second core dielectric substrate wherein an air gap is left therebetween.
    Type: Grant
    Filed: April 5, 2016
    Date of Patent: May 15, 2018
    Assignee: Compass Technology Company Limited
    Inventors: Kelvin Po Leung Pun, Chee Wah Cheung
  • Patent number: 9962676
    Abstract: Disclosed herein is a method of: treating an organic polymer with an electron beam-generated plasma; exposing the treated polymer to air or an oxygen- and hydrogen-containing gas, generating hydroxyl groups on the surface of the polymer; reacting the surface with an organosilane compound having a chloro, fluoro, or alkoxy group and a functional or reactive group that is less reactive with the surface than the chloro, fluoro, or alkoxy group; and covalently immobilizing a biomolecule to the functional or reactive group or a reaction product thereof.
    Type: Grant
    Filed: March 31, 2015
    Date of Patent: May 8, 2018
    Assignee: The United States of America, as represented by the Secretary of the Navy
    Inventors: Stella H. North, Evgeniya H. Lock, Scott G. Walton, Chris Rowe Taitt
  • Patent number: 9938376
    Abstract: A furan-based polyamide is prepared by the following steps: (1) preparing a furan-based oligomer of formula (1) H2N—R—(NH—CO—F—CO—NH—R)n—NH2 (1) where R is a hydrocarbon moiety and F is a furan (cyclo-C4H2O) moiety and n represents the average degree of oligomerization, and where n is within the range of 1 to 10 by reacting 2,5-furandicarboxylic acid or its derivative with a diamine at a temperature of at most 100° C.; (2) contacting the oligomer of step (1) with a bifunctional linker selected from an acid or a derivative thereof where the acid is furandicarboxylic acid or a non-aromatic dicarboxylic acid; provided that if the hydrocarbon moiety R is aromatic, then the bifunctional linker is an aromatic dicarboxylic acid or a derivative thereof, at a mole ratio of the oligomer to the difunctional linker within the range of 0.8 to 1.5 at polycondensation conditions, and (3) isolating the resulting polyamide.
    Type: Grant
    Filed: October 21, 2014
    Date of Patent: April 10, 2018
    Assignee: Synvina C.V.
    Inventors: Ate Duursma, Rene Aberson, Dee Dee Smith, Joel Flores, Matheus Adrianus Dam, Gerardus Johannes Maria Gruter
  • Patent number: 9896412
    Abstract: A compound of the general formula X-[Q-W—(CH?CH)n—(CH2)2-L]m (I) in which X represents a polymer; Q represents a linking group; W represents an electron-withdrawing group; n represents 0 or an integer of from 1 to 4; L represents a leaving group; and m represent an integer of from 1 to 8. The compounds find use in the conjugation of biological molecules.
    Type: Grant
    Filed: November 21, 2013
    Date of Patent: February 20, 2018
    Assignee: POLYTHERICS LIMITED
    Inventor: Antony Godwin
  • Patent number: 9801892
    Abstract: Fulvestrant formulations suitable for intramuscular injection at concentration in excess of 40 mg/ml in the absence of castor oil and castor oil derivatives are disclosed.
    Type: Grant
    Filed: November 6, 2015
    Date of Patent: October 31, 2017
    Assignee: HAZ TWO, LLC
    Inventor: Nageswara R. Palepu
  • Patent number: 9801978
    Abstract: Medical constructs with collagen fibers and gelatin and related collagen fibers. The collagen fibers can be derived from extruded soluble dermal collagen and can include a gelatin film attached to the at least one collagen fiber. The gelatin film can include one or more minerals and has a gelatin concentration of between about 0.1% to about 40% weight per volume.
    Type: Grant
    Filed: October 5, 2015
    Date of Patent: October 31, 2017
    Assignee: MiMedx Group, Inc.
    Inventors: Leon Paulos, Mengyan Li, Daniel Hernandez, Thomas Koob
  • Patent number: 9790286
    Abstract: This invention discloses the creation of a novel single ligand-targeted multi-stereoisomer peptide-polymer conjugate compounds comprising a group of different synthetic and chemically modified stereoisomer peptides that have been conjugated to a biocompatible polymer carrying a peptide ligand for targeted delivery and/or encapsulated in ligand targeted polymer nanoparticles. The unique physicochemical properties of the stereoisomer peptides provide therapeutic compounds with ideal biopharmaceutical properties. The stereoisomer peptides carried by the polymer are delivered to cells or tissues to inhibit, suppress, block, antagonize or disrupt, simultaneously and independently, the functional domain of different disease causing proteins.
    Type: Grant
    Filed: October 23, 2014
    Date of Patent: October 17, 2017
    Inventor: Lucia Irene Gonzalez
  • Patent number: 9744246
    Abstract: The present invention relates to a macromolecule comprising a dendrimer having surface amino groups to which at least two different terminal groups are attached including a pharmaceutically active agent and a pharmacokinetic modifying agent, the pharmaceutically active agent comprising a hydroxyl group and being attached to the surface amino group of the dendrimer through a diacid linker. Pharmaceutical compositions comprising the macromolecules and methods of treatment using the macromolecules are also described.
    Type: Grant
    Filed: June 6, 2012
    Date of Patent: August 29, 2017
    Assignee: STARPHARMA PTY LTD
    Inventors: David Owen, Brian Devlin Kelly, Peter Karellas
  • Patent number: 9731288
    Abstract: The present invention provides novel and improved stimulus responsive polymers and methods of using the same for the purification of biomolecules.
    Type: Grant
    Filed: November 13, 2015
    Date of Patent: August 15, 2017
    Assignee: EMD Millipore Corporation
    Inventors: Jad Jaber, Wilson Moya, James Hamzik, Arezki Boudif, Yu Zhang, Neil Soice, John Charkoudian, Nripen Singh
  • Patent number: 9625467
    Abstract: A method and related agent for detecting novel post-translational modification. This novel post-translational modification is in the form of crotonylation of lysine residues in proteins. The method includes the steps of (a) preparing a mixture of polypeptides from a protein sample; (b) separating the polypeptides by molecular weight; (c) contacting the separated polypeptides with a binding affinity reagent which binds specifically to a polypeptide containing a crotonyllysine residue; and (d) detecting presence of a binding complex between the affinity reagent and one or more of the polypeptides. An example of the binding agent is an antibody, which may be prepared from animal serums, or is a monoclonal antibody or single-chain variable fragment.
    Type: Grant
    Filed: May 27, 2011
    Date of Patent: April 18, 2017
    Assignee: PTM BIO LLC
    Inventor: Yingming Zhao
  • Patent number: 9555119
    Abstract: Disclosed herein is a delivery composition for administering a hydrophobic active agent. In one embodiment, a delivery composition for local administration of a hydrophobic active agent to a tissue or organ of a patient is disclosed. In one embodiment, the delivery composition includes a cationic delivery agent, a therapeutically effective amount of a hydrophobic active agent and a pharmaceutically acceptable aqueous carrier. In one embodiment, the cationic delivery agent includes polyethyleneimine (PEI). In a more specific embodiment, the cationic delivery agent includes branched PEI. Methods of making the delivery composition, as well as kits and methods of use are also disclosed.
    Type: Grant
    Filed: November 5, 2013
    Date of Patent: January 31, 2017
    Assignee: Surmodics, Inc.
    Inventors: Joseph Ventura, Shannon Wadman, Joram Slager, Joseph Schmidt McGonigle, Robert W. Hergenrother
  • Patent number: 9549901
    Abstract: A particle includes an aqueous core; a first amphiphilic layer surrounding the aqueous core; and a polymeric matrix surrounding the first amphiphilic layer.
    Type: Grant
    Filed: September 2, 2011
    Date of Patent: January 24, 2017
    Assignees: The Brigham and Women's Hospital, Inc., Massachusetts Institute of Technology
    Inventors: Jinjun Shi, Zeyu Xiao, Cristian Vilos, Alexander Votruba, Robert S. Langer, Omid C. Farokhzad